{
    "2019-02-22": [
        [
            {
                "time": "2018-11-15",
                "original_text": "Novartis gene therapy would be cost effective up to $900,000 -U.S. group",
                "features": {
                    "keywords": [
                        "Novartis",
                        "gene therapy",
                        "cost effective",
                        "$900,000",
                        "U.S. group"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-15",
                "original_text": "Novartis gene therapy is cost effective at up to $900,000 -U.S. group",
                "features": {
                    "keywords": [
                        "Novartis",
                        "gene therapy",
                        "cost effective",
                        "$900,000",
                        "U.S. group"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-02-25",
                "original_text": "Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 25, 2019",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Ex-Dividend Date",
                        "February 25, 2019"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}